IRCT20200417047113N1 IRCT 2020-04-24 Middle East Gene Therapy corporation Effect of NK cell therapy in COVID-19 Evaluating the safety and efficacy of allogeneic NK cells on COVID-19 induced pneumonia, double blind, randomized clinical trial 2020-04-27 anticipated 70 Complete https://irct.ir/trial/47264 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to one of the 7 study groups using random number table and receive intervention from the same group, Blinding description: In this study all participants will be blinded, including COVID-19 patients, the principal investigator who is an infectious disease specialist, as well as all physicians, nurses and treatment teams, as well as data collection officials and those who assessed the consequences after interventions. The patients in the study are divided into distinct groups according to the random algorithm. َA code is considered for each person and placed in an envelope, or a electronic file then presented to the physicians and the nurses. Elsewhere, it is clear that the code is related to the drug or placebo. When prescribing, the patient's code must be matched with the code on the cell product by the responsible physician and nurse. Only if the person's health is compromised, the code will be broken prematurely. This code also is unique for each individual, and if a code is broken, physician and researcher will not know the other patient's codes. 1-2 Condition 1: COVID-19. Condition 2: COVID-19. Condition 3: Viral pneumonia. Intervention 1: Intervention group 1: treatment group A, 0.1 * 107 NK cells per kilogram of patient weight. The lowest dose of cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after cell injection for safety and efficacy effects. Intervention 2: Intervention group 2: treatment group B, 0.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 3: Intervention group 3: treatment group C, 1 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 4: Intervention group 4: treatment group D, 1.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 5: Intervention group 5: treatment group E, 2 * 107 NK cells per kilogram of patient weight. The highest dose of cells will be injected into this treatment cohort. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 6: Intervention group 6: placebo, in this group, only physiological serum will be injected into patients. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 7: Control group: They do not receive any treatment other than common medications. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information.